Oncolytic Virus Therapy Market By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Vaccinia Virus, Newcastle Disease Virus (NDV), Reovirus, Others), By Application (Melanoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Others), By Therapy Type (Monotherapy, Combination Therapy), By Route of Administration (Intratumoral, Intravenous, Others), By End-user (Hospitals, Cancer Research Institutes, Specialty Clinics, Others.), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Virus Type

• Adenovirus
• Herpes Simplex Virus (HSV)
• Vaccinia Virus
• Newcastle Disease Virus (NDV)
• Reovirus
• Others

By Application

• Melanoma
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Others

By Therapy Type

• Monotherapy
• Combination Therapy

By Route of Administration

• Intratumoral
• Intravenous
• Others

By End-user

• Hospitals
• Cancer Research Institutes
• Specialty Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Amgen Inc.
• Oncolytics Biotech Inc.
• SillaJen Inc.
• Vyriad Inc.
• Targovax ASA
• Lokon Pharma AB
• Transgene SA
• PsiOxus Therapeutics
• ViroCure Inc.
• Virttu Biologics Ltd.
• Genelux Corporation
• BioVex Inc.
• Replimune Group Inc.
• CG Oncology Inc.
• Virogin Biotech Ltd.